Financial Services

Brookfield Corporation (BN)

$89.2B
Market Cap
80.4
P/E Ratio
1.86
Beta
0.72%
Dividend Yield
Piotroski 6/9Altman Z 0.5 DistressBeneish M -2.51 CleanROIC−WACC -3.6%

Quantitative Summary

Deterministic

BN trades at 80.4x earnings — a 319% premium to its sector average of 19.2x — without a dominant ROIC-WACC spread. Financial health is average: Piotroski 6/9, Altman Z 0.5.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics of this financial services entity reveal a significant divergence between capital efficiency and profitability generation. The company is currently destroying value, evidenced by an ROIC-WACC spread of -3.6%, indicating that returns on invested capital fall substantially short of the cost of equity and debt combined. While the Piotroski F-Score of 6/9 suggests moderate financial strength relative to peers, this is sharply contrasted by a distressing Altman Z-Score of 0.5, which flags a high probability of bankruptcy under standard models. Profitability metrics further underscore these structural challenges; net margins have compressed to just 1.7% while revenue contracted 12.7% year-overyear, suggesting that operational leverage and margin expansion are currently absent from the DuPont decomposition of returns. Although the negative Beneish M-Score of -2.51 points toward low earnings manipulation risk, it does not mitigate the severe capital destruction evident in the spread data or the precarious solvency indicators implied by the Z-score.

Valuation metrics present a stark disconnect between current market pricing and traditional valuation anchors for the sector. Trading at 80.4x forward earnings, the stock commands a premium more than four times the sector average of 18.3x, implying that investors are pricing in aggressive future growth or expecting a fundamental regime shift not yet reflected in historical performance. This extreme multiple is difficult to reconcile with the observed revenue contraction and thin net margins, as standard DCF frameworks would require sustained hyper-growth to justify such a valuation relative to the current cost of capital. The market appears to be betting on a rapid turnaround that has not materialized in recent financial statements, creating a scenario where implied growth rates vastly exceed actual operational performance.

Insider activity adds another layer of caution to the risk-reward profile, with $4.9 million in net selling over the past 90 days signaling significant distribution by those closest to the business prospects. While specific Fama-French alpha data or detailed leverage ratios were not provided to fully quantify factor exposure, the combination of negative capital returns, high bankruptcy risk, and substantial insider outflows suggests a heightened downside trajectory unless fundamental inflection points occur soon. The convergence of these factors paints a picture where current valuations may be detached from near-term operational realities, leaving investors exposed to potential mean reversion risks without clear catalysts visible in the provided dataset.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

Valuation Context

80.4x
BN P/E
19.2x
Sector Avg
+319%
vs Sector

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
0.5
Altman Z-Score
Distress Zone — below 1.8 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.51
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

24.1%
Gross Margin
1.7%
Net Margin
3.8%
ROIC
7.5%
WACC
ROIC − WACC Spread: -3.6%— Negative spread.
-12.7%
Revenue Growth (YoY)
+103.9%
Earnings Growth (YoY)
-3.8B
Free Cash Flow

Balance Sheet Health

2.12x
Debt / Equity
0.85x
Current Ratio
1.3x
Interest Coverage
6.4x
Net Debt / EBITDA
-1.29%
FCF Yield
31.8B
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
-$5M
Net Selling
1
Buy Transactions
4
Sale Transactions
2026-02-23Blidner (Jeffrey Miles)Other111,247 shares
2026-02-23Blidner (Jeffrey Miles)Grant$100M
2026-02-23Blidner (Jeffrey Miles)Other111,247 shares
2026-02-23Flatt (J. Bruce)Grant$19M
2026-02-23Flatt (J. Bruce)Grant$174M

Open-market buys vs sells by company insiders. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

6.7
Forward P/E
PEG Ratio
2.02
Price/Book
6M
Avg Volume
$49.57
52W High
$29.07
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$1.7B
Tracked Passive Exposure
8
ETFs Holding BN
0.14%
Avg Weight in ETFs
$1.2T
Total ETF AUM

When investors buy or sell ETFs like VIGI or VGK, the fund manager is mechanically forced to buy or sell BN shares regardless of Brookfield Corporation's individual fundamentals. We estimate $1.7B of passive capital is structurally linked to BN through 8 tracked ETFs. Index rebalances and ETF creation/redemption cycles can create noticeable volume spikes unrelated to company news.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in Brookfield Corporation to visualize passive redemption contagion across ETFs and collateral stocks.

BN Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
BNEpicenterVXUSETFVEAETFVEUETFNOVNUnknownNESNUnknownROPMed RiskRYHigh RiskASMLLow Risk
BN Price Drop (%)0

If Brookfield Corporation (BN) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Novartis AG (NOVN) as the most exposed collateral stock, sharing 5 ETFs with BN. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 10 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

BN Ownership Dynamics

Ticker
BN

Float lock-up computed from 10 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

BN Capital Efficiency

How efficiently does Brookfield Corporation convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$-3,794,000,000
EBITDA
$31.8B
FCF Conversion
-12%
Reinvestment Rate
112%
-12% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
3.8%
ROIC − WACC Spread
-3.6%

Brookfield Corporation converts -12% of its EBITDA into free cash flow, negative FCF conversion — the company is consuming cash faster than it generates EBITDA, which is unsustainable long-term. The 112% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-3.6%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-08360$46.51$16,743.6
2026-05-0714,401$46.45$668,926.45
2026-05-058,172$44.98$367,576.56
2026-05-041,133,684$45.23$51.3M
2026-04-28150$44.82$6,723
2026-04-275,847$45.48$265,921.56
2026-04-24746$45.36$33,838.56
2026-04-22598$46.44$27,771.12
2026-04-21301$46.66$14,044.66
2026-04-2028,070$46.59$1.3M
2026-04-15311$45.55$14,166.05
2026-04-1327,624$42.14$1.2M
2026-04-0733$40.76$1,345.08
2026-04-061,379$40.89$56,387.31
2026-03-314$38.72$154.88
2026-03-302,837$39.00$110,643
2026-03-1969,497$39.25$2.7M
2026-03-1150,230$41.69$2.1M
2026-03-09736,467$41.20$30.3M
2026-03-02106,943$43.84$4.7M
2026-02-2421,245$44.00$934,780
2026-02-1840,379$47.78$1.9M
2026-02-17332,691$47.79$15.9M
2026-02-1331,919$47.67$1.5M
2026-02-103,705$46.87$173,653.35
2026-02-0418$44.63$803.34
2026-02-0352,790$46.59$2.5M
2026-01-28216$47.42$10,242.72
2026-01-274,181$46.98$196,423.38
2026-01-2232,292$46.30$1.5M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare BN to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.